Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/04/2020.
Displaying: 121 trials in your specialties ()
View trials across your selected specialties

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metas...
View Full Trial
INTERVENTION

Other: Pharmacological Study, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non-Hodgkin's Lymphoma, Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Lenalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Saint Francis/Mount Sinai Regional Cancer Center, Hartford, Connecticut, United States

Brief Summary

The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    T Cell Lymphoma
View Full Trial
INTERVENTION

Drug: Tenalisib, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Brief Summary

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Colorectal Cancer
View Full Trial
INTERVENTION

Drug: Oral CC - 486, Drug: Romidepsin, Drug: MK - 3475

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Brief Summary

This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoma, Relapsed/Refractory T-cell Lymphomas
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Bortezomib, Drug: duvelisib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Stanford University Medical Center, Stanford, California, United States

Brief Summary

The purpose of this study is to test the safety of a study drug called duvelisib.

A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome
View Full Trial
INTERVENTION

Drug: Pembrolizumab, Radiation: Radiotherapy

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Guys & St Thomas's NHS Foundation Trust, London, United Kingdom

Brief Summary

Trial Subjects (patients), will receive single infusions of pembrolizumab every 3 weeks until disease progression or unacceptable toxicity develops. They will receive radiotherapy at week 12.

Entinostat Neuroendocrine (NE) Tumor

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Neuroendocrine Tumors
View Full Trial
INTERVENTION

Drug: Entinostat

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Columbia University Medical Center, New York, New York, United States

Brief Summary

This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE) tumors. Patients will continue on treatment until disease progression or intolerable toxicity occurs.

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    T Cell Non-Hodgkin Lymphoma
View Full Trial
INTERVENTION

Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moffitt Cancer Center, Tampa, Florida, United States

Brief Summary

The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic ...
View Full Trial
INTERVENTION

Drug: Ro-CHOEP-21 (PHASE I), Drug: Ro-CHOEP-21 (PHASE II)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy

Brief Summary

This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Previously Treated Unresectable or Metastatic Cholangiocarcinoma ...
View Full Trial
INTERVENTION

Drug: Entinostat, Drug: Nivolumab, Drug: Entinostat, Drug: Nivolumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Brief Summary

The proposed study is an open-label, two-arm study of entinostat plus nivolumab in patients with unresectable or metastatic CCA or PDAC.